Creative Medical Technology Holdings (CELZ) Change in Receivables (2017 - 2022)
Creative Medical Technology Holdings (CELZ) posted quarterly Change in Receivables of -$2485.0 for Q1 2022, down 200.0% quarter-over-quarter from $2485.0 in Q4 2021.
Creative Medical Technology Holdings (CELZ) Change in Receivables (2017 - 2022) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Change in Receivables for 6 consecutive years, with -$2485.0 the latest figure, recorded in Q1 2022.
- In Q1 2022, Change in Receivables changed N/A year-over-year to -$2485.0; the TTM figure through Dec 2022 stood at -$2485.0 (down 200.0% YoY), while the FY2022 annual figure was -$2485.0, down 200.0% from the prior year.
- Change in Receivables retreated to -$2485.0 in Q1 2022 per CELZ's latest filing, from $2485.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $18900.0 in Q4 2019 and bottomed at -$23500.0 in Q3 2019.
- Historically, Change in Receivables has averaged $1107.6 across 5 years, with a median of $1400.0 in 2020.
- On a YoY basis, Change in Receivables climbed as much as 529.55% in 2019 and fell as far as 355.43% in 2019.
- Creative Medical Technology Holdings' Change in Receivables stood at -$4400.0 in 2018, then soared by 529.55% to $18900.0 in 2019, then sank by 92.59% to $1400.0 in 2020, then surged by 77.5% to $2485.0 in 2021, then slumped by 200.0% to -$2485.0 in 2022.
- Business Quant data shows CELZ's Change in Receivables at -$2485.0 in Q1 2022, $2485.0 in Q4 2021, and $1400.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Creative Medical Technology Holdings | 1.88 Mn | 1.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -2,485.00 |
| Mar 31, 2022 | -2,485.00 |
| Dec 31, 2021 | 2,485.00 |
| Dec 31, 2021 | 2,485.00 |
| Sep 30, 2020 | 1,400.00 |
| Sep 30, 2020 | 1,400.00 |
| Jun 30, 2020 | 7,000.00 |
| Jun 30, 2020 | 7,000.00 |
| Mar 31, 2020 | -2,800.00 |
| Mar 31, 2020 | -2,800.00 |
| Dec 31, 2019 | 18,900.00 |
| Dec 31, 2019 | 18,900.00 |
| Sep 30, 2019 | -23,500.00 |
| Sep 30, 2019 | -23,500.00 |
| Jun 30, 2019 | 18,037.00 |
| Jun 30, 2019 | 18,037.00 |
| Mar 31, 2019 | -9,437.00 |
| Mar 31, 2019 | -9,437.00 |
| Dec 31, 2018 | -4,400.00 |
| Dec 31, 2018 | -4,400.00 |